Revenue Interest Purchase Agreement - Additional Information (Details) - Purchase Agreement - OrbiMed - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Sep. 12, 2022 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2025 |
Dec. 31, 2024 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Upfront payment received | $ 125,000,000 | ||||
| Potential revenue interest second payment to be received | $ 75,000,000 | ||||
| Purchase agreement, second payment date | Sep. 12, 2025 | ||||
| Potential revenue interest third payment to be received | $ 50,000,000 | ||||
| Purchase agreement, third payment date | Sep. 12, 2025 | ||||
| Revenue interest payment term | 45 days | ||||
| Amortization of purchase agreement obligation | $ 0 | ||||
| Effective interest rate | 8.90% | 8.90% | |||
| Debt issuance costs | $ 600,000 | $ 600,000 | |||
| Revenue interest payable | $ 2,944,000 | $ 2,623,000 | $ 2,900,000 | $ 2,400,000 | |
| Maximum | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Potential revenue interest payment to be received | $ 125,000,000 | ||||